Want to track ATHE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Alterity (ATHE) Up on Interim Data From Advance MSA Study
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
Zacks | 1 year ago
2025 © Marketlog. All Rights Reserved.
